Ushering in a New Era
In Cellular Medicine
Making personalized cell-therapy a reality for every patient with a degenerative microvascular disease.
Treatments are produced from the patients’ own cells, mimicking the body’s’ natural processes.
BioGenCell is dedicated to changing the lives of patients suffering from degenerative microvascular diseases, stopping disease progression, reversing disability, reducing pain, and enhancing functionality.
New, Accessible Tools for Physicians
Vascular diseases are the primary cause of mortality worldwide, representing 25% of fatalities. BioGenCell’s groundbreaking cell-therapy treatments aim to provide more accessible, reliable and cost-effective therapeutic options, with the hope of significantly impacting these tragic figures.
Our Ground-Breaking Phase 2 BGC101 Clinical Trial
Join a Journey that Brings New Hope to No-Option Chronic Limb-Threatening Ischemia (CLTI) Patients with BioGenCell’s Phase 2 Clinical Trial for BGC101.
Are you a Healthcare Provider?
Are you a CLTI (CLI) Patient?
Our Technology: TRACT
Tissue Regenerative Activated Cell Therapy
Transforming Your Blood into a Personalized Medicine in 3 Steps
A Potential Pipeline of Solutions:
From Treating Microvascular No-Option Patients to Improving the Lives of Patients Suffering from a Wide Range of Conditions
Other Unmet Needs
Cardiac Diseases, Ischemic Brain Diseases, Cancer, Immunological Disorders, Trauma and More
BioGenCell’s Phase 2 Clinical Trial assesses the safety and efficacy of the BGC101 cell therapy in treating Chronic Limb-Threatening Ischemia.
Discover a Potential Treatment Option for Chronic Limb-Threatening Ischemia
Clinical Trials Gov Identifier: NCT02805023
We Are Actively Recruiting
Combining Experience and Passion
Our team of experts brings to the table decades of experience and an unbridled passion for biomedicine. We have set our sights on improving patients lives by making cell therapy simple and accessible, patients friendly – and physician friendly.